Efficacy of interventions on the relief of symptoms in IBS: relative risk (RR) or OR and CI based on systematic reviews and meta-analyses
| Intervention | Parameter | RR or OR | Ref. # |
|---|---|---|---|
| Dietary or probiotics or antibiotics | |||
| Bran, ispaghula and unspecified fibre | Abdominal pain | RR 0.87 (0.76 to 1.00) | 21 |
| Low FODMAP diet | Abdominal pain | OR 1.81 (1.13 to 2.88) | 24 |
| Probiotics | Global improvement | SEM: −0.25 (−0.36 to −0.14) | 40 |
| Probiotics: combination of Escherichia coli and Enterococcus faecalis or E. coli alone | Abdominal pain | RR 1.96 (1.14 to 3.36) | 42 43 |
| Rifaximin Rifaximin | Global improvement | OR 1.57 (1.22 to 2.01) | 48 |
| Bloating | OR 1.55 (1.23 to 1.96) | 48 | |
| Antispasmodics | |||
| Peppermint oil | Global improvement | RR 2.23 (1.78 to 2.81) | 70 |
| Antidepressants | |||
| Antidepressant therapy | Global improvement | RR 0.66 (0.57 to 0.78) | 72 |
| Abdominal pain | RR 0.62 (0.43 to 0.88) | 72 | |
| Antidepressant therapy | Global improvement | RR 0.67 (0.58 to 0.77) | 73 74 |
| Antidepressant therapy | Abdominal pain | RR 0.62 (0.43 to 0.88) | 73 74 |
| Drugs targeting specific GI receptors | |||
| Alosetron | Abdominal pain and discomfort | RR 1.30 (1.22 to 1.39) | 81 |
| Overall risk difference | 0.13 (0.1 to 0.16) | 81 | |
| Alosetron | Abdominal pain and discomfort | RR 1.23 (1.15 to 1.32) | 82 |
| Global improvement | RR 1.5 (1.40 to 1.72) | 82 | |
| Ondansetron | Adequate relief response | RR 4.7 (2.6 to 8.5) | 86 |
| Linaclotide | Adequate relief response | RR 1.95 (1.3 to 2.9) | 94 |
| Abdominal pain | RR 1.58 (1.02 to 2.46) | 94 | |
FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyol.